Skip to content

Observation on the therapeutic efficacy of combining acupoint application with targeted transdermal drug therapy for diabetic peripheral neuropathy characterized by qi deficiency and blood stasis

Observation on the therapeutic efficacy of combining acupoint application with targeted transdermal drug therapy for diabetic peripheral neuropathy characterized by qi deficiency and blood stasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085265
Enrollment
Unknown
Registered
2024-06-04
Start date
2024-06-04
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic peripheral neuropathic pain

Interventions

intervention group:Acupoint application combined with directional penetration
Control group:Placebo patch combined with directional penetration

Sponsors

Yueyang Hospital of Integrated Traditional Chinese Medicien and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the Western medical diagnostic criteria for diabetic peripheral neuropathy; (2) Meet the diagnostic criteria of TCM syndrome Qi deficiency and blood stasis; (3) Age =18 years old and =80 years old, gender is not limited; (4) Volunteer to participate in this clinical trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients who are known to be allergic to the investigational drug or its components; (2) Peripheral neuropathy caused by non-type 2 diabetes: Understand the patient's past medical history and drug use history, and improve cervical MRI, lumbar MRI, head MRI and other examinations when necessary. (3) Complicated with serious diseases such as heart, liver and kidney: creatinine and urea nitrogen in blood are more than 1.5 times of the normal range, AST and ALT are more than 3 times of the normal range. (4) People with mental disorders; (5) Other serious complications of diabetes; Diabetic ketoacidosis, diabetic nephropathy terminal renal failure stage, diabetic retinopathy proliferative stage. (6) Skin rupture or other infectious skin diseases at the application site; (7) Patients with cardiac pacemakers and metal implants in the body; (8) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Toronto rating scale;

Secondary

MeasureTime frame
Traditional Chinese Medicine Syndrome Score Scale;Neuroelectrophysiological detection;Michigan diabetic neuropathy Score;Biochemical indicators;

Countries

China

Contacts

Public ContactHe Yanming

Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine

heyanming176@163.com+86 133 8619 3310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026